Mei Pharma Stock Buy Hold or Sell Recommendation
| MEIP Stock | USD 2.70 0.10 3.57% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding MEI Pharma is 'Cautious Hold'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell MEI Pharma within the specified time frame.
Check out MEI Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in MEI Stock, please use our How to Invest in MEI Pharma guide. Note, we conduct extensive research on individual companies such as MEI and provide practical buy, sell, or hold advice based on investors' constraints. MEI Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
MEI |
Execute MEI Pharma Buy or Sell Advice
The MEI recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on MEI Pharma. Macroaxis does not own or have any residual interests in MEI Pharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute MEI Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
MEI Pharma Trading Alerts and Improvement Suggestions
| MEI Pharma generated a negative expected return over the last 90 days | |
| MEI Pharma has high likelihood to experience some financial distress in the next 2 years | |
| MEI Pharma currently holds about 153.25 M in cash with (50.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15. | |
| Latest headline from thelincolnianonline.com: MEI Pharma Research Coverage Started at StockNews.com |
MEI Pharma Returns Distribution Density
The distribution of MEI Pharma's historical returns is an attempt to chart the uncertainty of MEI Pharma's future price movements. The chart of the probability distribution of MEI Pharma daily returns describes the distribution of returns around its average expected value. We use MEI Pharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of MEI Pharma returns is essential to provide solid investment advice for MEI Pharma.
| Mean Return | -0.16 | Value At Risk | -3.05 | Potential Upside | 2.96 | Standard Deviation | 2.36 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of MEI Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
MEI Stock Institutional Investors
The MEI Pharma's institutional investors refer to entities that pool money to purchase MEI Pharma's securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Northern Trust Corp | 2024-09-30 | 23 K | State Street Corp | 2024-09-30 | 17.8 K | Susquehanna International Group, Llp | 2024-09-30 | 13.4 K | Ubs Group Ag | 2024-09-30 | 12.9 K | Squarepoint Ops Llc | 2024-09-30 | 10.7 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 5.8 K | Newbridge Financial Services Group, Inc. | 2024-09-30 | 2 K | Group One Trading, Lp | 2024-09-30 | 2 K | Tower Research Capital Llc | 2024-09-30 | 1.6 K | Anson Funds Management Lp | 2024-09-30 | 1.1 M | Cable Car Capital Llc | 2024-09-30 | 611.4 K |
MEI Pharma Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 2.7M | (3.8M) | 7.2M | 1.2M | (13.2M) | (12.5M) | |
| Other Non Cash Items | 23.1M | (18.1M) | (19.8M) | 1.4M | 13.4M | 14.0M | |
| Capital Expenditures | 894K | 708K | 479K | 35K | 7K | 6.7K | |
| Net Income | (46.0M) | (50.6M) | (54.5M) | (31.8M) | 17.8M | 18.7M | |
| End Period Cash Flow | 12.3M | 8.5M | 15.7M | 16.9M | 3.7M | 3.5M | |
| Free Cash Flow | 33.4M | (32.7M) | (49.2M) | (52.5M) | (50.5M) | (48.0M) | |
| Depreciation | 109K | 285K | 326K | 386K | 383K | 402.2K | |
| Change To Inventory | 2.3M | (15.7M) | 2.5M | (10.0M) | (9.0M) | (8.5M) | |
| Change To Netincome | 7.0M | (7.9M) | (11.5M) | 3.9M | 3.5M | 3.7M | |
| Investments | (105.4M) | 25.4M | 7.4M | 53.7M | 49.1M | 51.6M |
MEI Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to MEI Pharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that MEI Pharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a MEI stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.23 | |
β | Beta against Dow Jones | 0.59 | |
σ | Overall volatility | 2.37 | |
Ir | Information ratio | -0.11 |
MEI Pharma Volatility Alert
MEI Pharma exhibits very low volatility with skewness of 2.77 and kurtosis of 15.18. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure MEI Pharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact MEI Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.MEI Pharma Fundamentals Vs Peers
Comparing MEI Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze MEI Pharma's direct or indirect competition across all of the common fundamentals between MEI Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as MEI Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of MEI Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing MEI Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare MEI Pharma to competition |
| Fundamentals | MEI Pharma | Peer Average |
| Return On Equity | 0.62 | -0.31 |
| Return On Asset | 0.2 | -0.14 |
| Profit Margin | 0.27 % | (1.27) % |
| Operating Margin | 0.40 % | (5.51) % |
| Current Valuation | (20.36 M) | 16.62 B |
| Shares Outstanding | 6.66 M | 571.82 M |
| Shares Owned By Insiders | 1.31 % | 10.09 % |
| Shares Owned By Institutions | 41.03 % | 39.21 % |
| Number Of Shares Shorted | 48.93 K | 4.71 M |
| Price To Earning | 30.29 X | 28.72 X |
| Price To Book | 0.72 X | 9.51 X |
| Price To Sales | 0.28 X | 11.42 X |
| Revenue | 65.3 M | 9.43 B |
| Gross Profit | 48.82 M | 27.38 B |
| EBITDA | 26.38 M | 3.9 B |
| Net Income | 17.78 M | 570.98 M |
| Cash And Equivalents | 153.25 M | 2.7 B |
| Cash Per Share | 1.15 X | 5.01 X |
| Total Debt | 8.36 M | 5.32 B |
| Debt To Equity | 0.18 % | 48.70 % |
| Current Ratio | 6.84 X | 2.16 X |
| Book Value Per Share | 4.96 X | 1.93 K |
| Cash Flow From Operations | (50.47 M) | 971.22 M |
| Short Ratio | 0.94 X | 4.00 X |
| Earnings Per Share | (6.99) X | 3.12 X |
| Price To Earnings To Growth | 20.60 X | 4.89 X |
| Target Price | 20.0 | |
| Number Of Employees | 28 | 18.84 K |
| Beta | 0.71 | -0.15 |
| Market Capitalization | 17.99 M | 19.03 B |
| Total Asset | 41.38 M | 29.47 B |
| Retained Earnings | (388.22 M) | 9.33 B |
| Working Capital | 32.41 M | 1.48 B |
Note: Acquisition by Kango Sujay of 87500 shares of MEI Pharma subject to Rule 16b-3 [view details]
MEI Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as MEI . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About MEI Pharma Buy or Sell Advice
When is the right time to buy or sell MEI Pharma? Buying financial instruments such as MEI Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having MEI Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Wholesale Thematic Idea Now
Wholesale
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Wholesale theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Wholesale Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.